SPB4 Antibody

Basic Research Questions

• What is Spherical Body Protein 4 and what is its biological significance?

Spherical Body Protein 4 (SPB4) is a protein originally identified in Babesia bigemina, a parasite that causes bovine babesiosis. The gene encoding SPB4 consists of 834 nucleotides without introns and encodes a protein of 277 amino acids. In silico analysis reveals that SPB4 contains a signal peptide that is cleaved at residue 20, producing a mature 28.88-kDa protein. The presence of this signal peptide combined with the absence of transmembrane domains suggests that SPB4 is a secreted protein .

The biological significance of SPB4 lies in its immunogenic properties. When cattle are immunized with recombinant B. bigemina SPB4, the resulting antibodies can identify both B. bigemina and B. ovata merozoites. More importantly, these antibodies can neutralize parasite multiplication in vitro for both species, indicating that SPB4 plays a crucial role in parasite-host interactions .

• What is SERPINB4 and how does it function?

SERPINB4 (Serpin Family B Member 4) is a member of the serpin family of serine protease inhibitors. This protein is highly expressed in many tumor cells where it functions to inactivate granzyme M, an enzyme involved in killing tumor cells. SERPINB4, along with its paralog SERPINB3, can be processed into smaller fragments that aggregate to form an autoantigen in psoriasis, potentially causing chronic inflammation .

At the molecular level, SERPINB4 functions through protease binding and inhibition. Diseases associated with SERPINB4 include Squamous Cell Carcinoma and Chromosome 18Q Deletion Syndrome. Its pathway involvement includes amoebiasis, and its GO annotations relate to enzyme binding and protease binding functions .

• What is Spb4 helicase and what role does it play in cellular processes?

Spb4 is an essential RNA helicase involved in the maturation of late nucleolar pre-60S ribosomal particles. It functions by restructuring ribosomal RNA (rRNA) during ribosome biogenesis. Specifically, Spb4 is required for the processing of 27SB pre-rRNA on pre-60S particles, and its depletion impairs the recruitment of Nog2, which is necessary for subsequent 27SB processing .

Structurally, Spb4 binds to pre-60S intermediates at a hinge region at the base of eukaryote-specific expansion segment 27 (ES27) within 25S rRNA domain IV. The helicase contains catalytic core domains and a C-terminal domain that is essential for pre-60S targeting. Mutations in the catalytic domains (K57R, E173A, R360A) are lethal or cause slow growth phenotypes, highlighting the critical nature of Spb4 in cellular function .

Advanced Research Questions

• How can researchers distinguish between SERPINB3 and SERPINB4 in immunoassays?

Distinguishing between SERPINB3 and SERPINB4 poses a significant challenge due to their high sequence homology. A methodological approach using hydrogel-based microarrays (biochips) has proven effective. In this approach:

• Create genetic constructs encoding full-length serpin B3 and serpin B4 molecules with N-terminal His6-tags

• Express and purify the recombinant proteins

• Design a biochip containing gel elements with:

  • Immobilized antibodies against SPB3

  • Immobilized commercial monoclonal SCC107 and SCC140 antibodies

  • Immobilized SPB3 or SPB4 proteins

Direct immunoassay experiments reveal that SPB4 binds effectively only to SCC107 and SCC140 antibodies, while SPB3 interacts not only with these antibodies but also with H3 and C5 monoclonal antibodies. Using a sandwich immunoassay approach, the pair of monoclonal antibodies SCC107/C5 has been identified to interact specifically with serpin B3 but not with serpin B4 .

This methodological approach enables selective determination of serpin B3 in the presence of highly homologous serpin B4, which is critical for accurate diagnostic and research applications.

• What is the relationship between anti-PF4 antibodies and disease severity in COVID-19?

A significant correlation has been established between anti-PF4 (platelet factor 4) antibodies and COVID-19 severity. Studies have found that anti-PF4 antibodies were detected in 95% of hospitalized patients with COVID-19, regardless of prior heparin treatment, with a mean optical density value of 0.871 ± 0.405 SD (range, 0.177 to 2.706) .

Analysis of demographic correlations revealed:

Linear regression analysis found significant correlations between anti-PF4 antibody levels and sex, race, ethnicity, circulating white blood cell counts, platelet reductions, and maximum disease severity scores. Multiple regression analysis confirmed that anti-PF4 antibody levels were independently associated with disease severity after adjusting for age, race, intravenous heparin treatment, and BMI .

The mechanism appears to involve PF4 directly interacting with the SARS-CoV-2 spike protein, leading to the formation of ultra-large molecular complexes. This interaction may expose cryptic immunogenic epitopes in PF4 that are recognized by the immune system, resulting in a multi-isotype antibody response .

• How does Spb4 interact with other factors in pre-60S ribosomal particle maturation?

Spb4 interacts with several factors during pre-60S ribosomal particle maturation, forming part of a complex remodeling machinery. Cryo-EM structural analyses have revealed that Spb4 works in coordination with:

• Rrp17 - Spb4 and Rrp17 bind to late nucleolar pre-60S particles directly prior to their transition to the nucleoplasm

• Rea1 AAA ATPase - Works concurrently with Spb4 for remodeling through rRNA restructuring

• Spb1 MTD (Methyltransferase Domain) - Spb4 incorporates around state D/E shortly prior to final Spb1 MTD and Rrp17 incorporation

The binding sequence has been elucidated through analysis of distinct nucleolar exit 1 (NE1)-like states downstream of Ytm1-Erb1 removal. Spb4 purifications revealed a mixture of these states as well as state E-like particles with weak densities for the L1 stalk, Rrp17, and the Spb1 MTD, representing intermediates upstream of state E .

The C-terminal domain (CTD) of Spb4 is essential for pre-60S targeting, although recent studies suggest that not the entire CTD is strictly required for pre-60S assembly. The integrated function of these factors creates a coordinated process for ribosome biogenesis that depends on both the catalytic and C-terminal domains of Spb4 .

• What approaches are used to identify conserved B-cell epitopes in SPB4 for vaccine development?

Identification of conserved B-cell epitopes in SPB4 for vaccine development employs a systematic methodology:

• Bioinformatic prediction: BLAST analysis on NCBI and Sanger Institute portals to identify peptides with the best prediction scores specific to B. bigemina SPB4

• Peptide synthesis and validation: Selected peptides are chemically synthesized as a multi-antigenic peptide system of eight branches (MAP8)

• Immunization and antibody production:

  • For recombinant full-length SPB4: 7-month-old steers immunized three times with 100 μg of rSBP4 emulsified with Montanide ISA 71 adjuvant (1:1)

  • For individual peptides: 8-week-old New Zealand rabbits immunized four times with 100 μg of each individual peptide suspended in PBS and emulsified with adjuvant

• Functional assessment: Testing sera for neutralizing capability against parasite invasion in vitro

  • Anti-peptide antibodies reduced parasite invasion by 57%, 44%, 42%, and 38% for peptides 1, 2, 3, and 4 respectively (p < 0.05)

• Field validation: Evaluation of sera from naturally infected cattle for recognition of the peptides to confirm real-world relevance

This integrated approach successfully identified four peptides with predicted B-cell epitopes that were conserved across 17 different isolates from six countries, demonstrating the potential of SPB4 as a vaccine candidate.

Methodological Questions

• What are the current methods for designing antibodies with specific binding profiles?

Contemporary antibody design employs a hybrid approach combining experimental selection with computational modeling to achieve precise binding specificity:

• Experimental selection (phage display):

  • Creation of minimal antibody libraries (e.g., single naïve human VH domain with variations in CDR3)

  • Selection against target ligands or complexes (e.g., DNA hairpin loops on streptavidin-coated beads)

  • Multiple rounds of selection with amplification steps between rounds

  • High-throughput sequencing to monitor library composition at each step

• Computational modeling and prediction:

  • Identification of different binding modes associated with particular ligands

  • Development of energy functions to model binding interactions

  • Optimization of sequences to either minimize functions (for cross-specific sequences) or both minimize and maximize functions (for specificity)

• AI-driven design approaches:

  • Use of models like RFdiffusion fine-tuned to design human-like antibodies

  • Specialized training for building antibody loops (the flexible regions responsible for binding)

  • Generation of novel antibody blueprints unlike any seen during training

• Experimental validation:

  • Testing designed antibodies against targets relevant to disease

  • Evaluation of binding affinity and specificity profiles

  • Assessment of functional outcomes in relevant biological assays

This integrative approach has applications for creating antibodies with both specific and cross-specific binding properties and for mitigating experimental artifacts and biases in selection experiments.

• What methodologies are used to evaluate anti-SPB4 antibody specificity and function?

Evaluating anti-SPB4 antibody specificity and function requires a multi-faceted methodological approach:

• Flow cytometry to confirm cell surface binding:

  • Compare fluorescence shift between cells with normal vs. overexpressed SPB4

  • Use appropriate controls (parental cell lines, isotype controls)

  • This confirms antibody binding to native, cell-surface expressed SPB4

• Western blot analysis for protein recognition:

  • Compare protein detection between control and SPB4-overexpressing cells

  • Verify expected molecular weight (e.g., 120 kDa for EphB4)

  • This confirms antibody specificity for the target protein

• Immunofluorescence for cellular localization:

  • Compare fluorescence patterns between control and SPB4-expressing cells

  • Assess cellular distribution and co-localization with relevant markers

  • This confirms antibody ability to recognize the protein in fixed cells

• Functional assays:

  • Cell viability assessment after antibody treatment (e.g., trypan blue exclusion)

  • Anchorage-independent growth assays to assess anti-cancer effects

  • Gene expression analysis to evaluate downstream effects on target genes

  • Protein level assessment via Western blot at different time points after antibody treatment

  • These assess the functional consequences of antibody binding

• Peptide exclusion/competition to identify specific epitopes:

  • Pre-incubate antibodies with synthetic peptides spanning the target protein

  • Test the ability of peptides to block antibody function

  • Identify the specific epitope recognized by functional antibodies

• In vivo models to confirm therapeutic potential:

  • Xenograft tumor models to assess anti-tumor activity

  • Measurement of tumor growth parameters

  • Histological and molecular analysis of treated tissues

This comprehensive approach ensures thorough characterization of antibody specificity and function for research and potential therapeutic applications.

• What expression systems and purification strategies are recommended for producing recombinant SPB4 proteins?

Production of recombinant SPB4 proteins requires careful consideration of expression systems and purification strategies:

For SERPINB4:

• Vector construction:

  • Create genetic constructs encoding full-length serpin B4 with N-terminal His6-tag

  • Ensure correct reading frame and inclusion of all necessary domains

• Expression system:

  • E. coli-based expression (BL-21 or similar strains)

  • Induction using appropriate methods (e.g., L-arabinose for arabinose-inducible promoters)

  • Optimize temperature, induction timing, and duration for maximum yield

• Purification approach:

  • Affinity chromatography using His-tag

  • Dialysis to remove imidazole and other purification reagents

  • Verification of correct tertiary structure through binding to conformation-specific antibodies

For Babesia SPB4:

• Cloning strategy:

  • Directional cloning in appropriate entry vectors (e.g., pENTR-D/TOPO)

  • Subcloning via recombination into expression vectors (e.g., pDEST-17)

  • Verification by restriction analysis and/or sequencing

• Expression optimization:

  • Transform E. coli BL-21 AI or similar strains

  • Set up pre-inoculum cultures for consistent growth

  • Monitor optical density and induce at optimal density (OD600 of ~0.4)

  • Use appropriate inducers (e.g., 0.2% L-arabinose)

• Purification considerations:

  • Assess protein solubility through pilot tests

  • Use appropriate purification methods based on solubility profile

  • Verify purity and structural integrity through functional assays

For both proteins, it's essential to verify correct folding through functional assays or antibody recognition tests to ensure that the recombinant protein maintains native-like properties necessary for downstream applications.

• How can peptide-based approaches be used to map functional epitopes in anti-SPB4 antibodies?

Peptide-based epitope mapping of anti-SPB4 antibodies involves a systematic approach to identify the precise binding regions that mediate functional effects:

• Design of overlapping peptide library:

  • Generate a series of peptides spanning the region of interest in the SPB4 protein

  • Typical peptide length: 15-25 amino acids with 5-10 amino acid overlaps

  • Example: In anti-EphB4 antibody studies, researchers divided a 200-amino acid sequence into six overlapping peptides

• Peptide exclusion/competition assays:

  • Pre-incubate antibodies with individual peptides or peptide cocktails

  • Test whether peptide binding blocks antibody function in cellular assays

  • Quantify the degree of inhibition for each peptide

  • In EphB4 studies, peptides 1 and 2 each blocked approximately 50% of antibody effect

• Peptide immobilization for antibody isolation:

  • Immobilize identified peptides onto affinity matrices (e.g., MicroLink gel)

  • Use the matrix to isolate specific antibodies from polyclonal preparations

  • Verify specificity of isolated antibodies through Western blot or other methods

  • In EphB4 studies, this approach successfully isolated antibodies that recognized only a single band at the expected molecular weight

• Minimal epitope refinement:

  • Generate smaller peptides within the identified region

  • Test these for binding and competitive inhibition

  • Identify the minimal amino acid sequence required for antibody recognition

• Structural analysis:

  • Use the identified epitope sequence to predict structural features

  • Assess conservation across species or related proteins

  • Determine whether the epitope is linear or conformational

This systematic approach not only identifies the specific binding region of functional antibodies but also provides insights into the structural basis of antibody function, facilitating the development of more targeted therapeutic or diagnostic approaches.

• What are the key considerations when developing neutralizing antibodies against SPB4 for potential therapeutic applications?

Developing neutralizing antibodies against SPB4 for therapeutic applications requires attention to several critical factors:

• Epitope selection and conservation:

  • Target conserved epitopes to ensure broad efficacy across different isolates/variants

  • In Babesia studies, four peptides with predicted B-cell epitopes were identified as conserved across 17 different isolates from six countries

  • Antibodies against these conserved peptides reduced parasite invasion by 37-57%

• Validation of neutralizing capacity:

  • Establish robust in vitro assays to quantify neutralization

  • For Babesia SPB4, this involved measuring reduction in parasite multiplication

  • Compare effectiveness against different strains or related species

• Cross-reactivity assessment:

  • Determine whether antibodies recognize homologous proteins (e.g., SPB3 vs. SPB4)

  • Develop specific detection methods to distinguish between closely related targets

  • For serpins, biochip-based assays can differentiate between SPB3 and SPB4

• Isotype and effector function optimization:

  • Consider antibody isotype based on desired effector functions

  • In COVID-19 studies, multi-isotype anti-PF4 antibody responses were observed, with IgM predominating

  • Evaluate complement-dependence of antibody effects (e.g., heat-inactivated vs. normal serum testing)

• Target cell specificity:

  • Assess effects on target vs. non-target cells

  • In EphB4 studies, antibodies affected cancer cell lines but not normal cells like MCF10A and HUVEC

  • Document differential sensitivity across various cell types:

  Cell Type	Cell Line	Response to Antibody
  Colon cancer	SW480, SW620	Significant cell death
  Breast cancer	MDA-MB-231, MCF-7	Significant cell death
  Bladder cancer	HT119	Significant cell death
  Bladder cancer	T24	No significant effect
  Prostate cancer	PC3	Significant cell death
  Prostate cancer	LNCaP	No significant effect
  Normal breast	MCF10A	No significant effect
  Normal endothelial	HUVEC	No significant effect

• Mechanism of action studies:

  • Determine whether antibodies cause protein degradation, signaling changes, or other effects

  • In EphB4 studies, antibody treatment caused down-regulation of gene expression and loss of protein

  • For PF4 antibodies in COVID-19, mechanism may involve recognition of spike protein-PF4 complexes

• Integration with computational design approaches:

  • Consider using AI methods like RFdiffusion to optimize antibody design

  • Focus on human-like antibodies to minimize immunogenicity

  • Target specific binding loops for engineering optimal specificity